Updated list of our EC-70124 publications…
9
9
- The multikinase inhibitor EC-70124 synergistically increased the antitumor activity of doxorubicin in sarcomas
- Estupiñán O, Santos L, Rodríguez A, Fernández-Nevado L, Costales P, Pérez-Escuredo J, Hermosilla MA, Oro P, Rey V, Tornín J, Allonca E, Fernández-García MT, Alvarez-Fernández C, Braña A, Astudillo A, Menéndez ST, Morís F, Rodríguez R
- Int J Cancer. 2018, Dec 21. doi: 10.1002/ijc.32081
8
- Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia
- Puente-Moncada N, Costales P, Antolín I, Núñez LE, Oro P, Hermosilla MA, Pérez-Escuredo J, Ríos-Lombardía N, Sanchez-Sanchez AM, Luño E, Rodríguez C, Martín V, Morís F
- Mol. Cancer Ther., 2018, Mar;17(3):614-624 doi: 10.1158/1535-7163.MCT-17-0530 PMID: 29339551
7
- EC-70124, a novel glycosylated indolocarbazole multi-kinase inhibitor, reverts tumorigenic and stem cell properties in prostate cancer by inhibiting STAT3 and NF-κB-
- Civenni G, Longoni N, Costales P, Dallavalle C, García-Inclán C, Nuñez L-E, Morís F, Carbone GM, Catapano CV.
- Mol. Cancer Ther. 2016, May;15(5): 806-18. doi: 10.1158/1535-7163.MCT-15-0791 PMID: 26826115
6
- Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors
- Serrano-Heras G, Cuenca-López MD, Montero JC, Corrales-Sánchez V, Morales JC, Núñez LE, Morís F, Pandiella A, Ocaña A.
- Oncotarget 2015, 6(31), 31272-83. doi: 10.18632/oncotarget.5211. PMID: 26418718
5
- Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer
- Cuenca-López MD, Serrano-Heras G, Montero JC, Corrales-Sánchez V, Gómez-Juárez M, Gascón-Escribano MJ, Morales JC, Voisin V, Núñez LE, Morís F, Bader GD, Pandiella A, Ocaña A.
- Oncotarget 2015, 6(29):27923-37. doi: 10.18632/oncotarget.4736. PMID: 26314846
4
- Chapter 6: Biosynthesis of Indolocarbazole Alkaloids and Generation of Novel Derivatives by Combinatorial Biosynthesis
- Carmen Méndez, Francisco Morís, José A. Salas
- RSC Drug Discovery Series 2012, 25(Drug Discovery from Natural Products) 99-115 (Edited by Olga Genilloud and Francisca Vicente).
3
- The NFκB pathway: a therapeutic target in glioblastoma
- Nogueira L, Ruiz-Ontañón P, Vázquez-Barquero A, Morís F, Fernández-Luna JL.
- Oncotarget. 2011Aug;2(8):646-53. Review. doi: 10.18632/oncotarget.322. PMID: 21896960
2
- Blockade of the NFκB pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivo
- Nogueira L, Ruiz-Ontañón P, Vázquez-Barquero A, Lafarga M, Berciano MT, Aldaz B, Grande L, Casafont I, Segura V, Robles EF, Suárez D, García LF, Martínez-Climent JA, Fernández-Luna JL.
- Oncogene. 2011 Aug 11;30(32):3537-48. doi: 10.1038/onc.2011.74. PMID: 21423202
1
- Generation of potent and selective kinase inhibitors by combinatorial biosynthesis of glycosylated indolocarbazoles
- Sánchez C, Salas AP, Braña AF, Palomino M, Pineda-Lucena A, Carbajo RJ, Méndez C, Morís F, Salas JA.
- Chem. Commun. (Camb). 2009 Jul 21;(27):4118-20. doi: 10.1039/b905068j. PMID: 19568652
